Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest announcement is out from Xilio Therapeutics ( (XLO) ).
On February 10, 2025, Xilio Therapeutics announced a collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies. The agreement includes an upfront payment of $52 million and potential contingent payments up to $2.1 billion. AbbVie will leverage its oncology expertise alongside Xilio’s proprietary technology to advance masked T cell engagers and other immunotherapies. This collaboration positions Xilio to accelerate its technology’s expansion into next-generation therapies, potentially enhancing its market presence and providing significant financial benefits.
More about Xilio Therapeutics
Xilio Therapeutics is a clinical-stage biotechnology company specializing in tumor-activated immuno-oncology therapies. The company aims to improve cancer treatment outcomes by localizing anti-tumor activity within the tumor microenvironment, thereby reducing systemic side effects.
YTD Price Performance: -38.60%
Average Trading Volume: 490,937
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $30.66M
For an in-depth examination of XLO stock, go to TipRanks’ Stock Analysis page.
